Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940250 | 1.00 | ESRRG (0.50) | ESRRGBCHEACHEKDM4EPOLB | |
| SCHEMBL3940244 | 1.00 | ESRRG (0.50) | ESRRGBCHEACHEKDM4EPOLB | |
| SCHEMBL4088098 | 0.87 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBPPARA | |
| SCHEMBL4088100 | 0.87 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBPPARA | |
| SCHEMBL4088102 | 0.87 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBPPARA | |
| SCHEMBL3947596 | 0.86 | CYP1A1 (0.48) | KDM4ECYP1A1CYP1B1MAOBPPARA | |
| SCHEMBL3947604 | 0.86 | CYP1A1 (0.48) | KDM4ECYP1A1CYP1B1MAOBPPARA | |
| SCHEMBL3947600 | 0.86 | CYP1A1 (0.48) | KDM4ECYP1A1CYP1B1MAOBPPARA | |
| SCHEMBL3940152 | 0.85 | CYP1A1 (0.59) | CYP1A1CYP1B1MAOB | |
| SCHEMBL3940154 | 0.85 | CYP1A1 (0.59) | CYP1A1CYP1B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | ESRRG 4328/4885BCHE 2071/4885ACHE 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.